Background
The Africa Centres for Disease Control and Prevention (Africa CDC), a specialized public health institution of the African Union (AU), invites eligible African vaccine manufacturers established and operating in African Union Member States to submit Bids for the supply of Yellow Fever Vaccine and Hexavalent Vaccine under the African Pooled Procurement Mechanism (APPM).
The procurement is open to all eligible African vaccine manufacturers that meet the requirements set out in the Bidding Document. It forms part of the continental effort to secure reliable access to quality-assured vaccines for African Union Member States.
Objective
The objective of this procurement is to:
● establish Framework Agreements with qualified African vaccine manufacturers for the supply of Yellow Fever Vaccine and Hexavalent Vaccine;
● secure timely, reliable and quality-assured vaccine supply for African Union Member States;
● strengthen sustainable African vaccine manufacturing capacity and reduce dependence on external supply chains;
● improve affordability and security of supply through aggregation of Member State demand;
● support routine immunisation programmes, outbreak preparedness and response, and public health emergencies;
● and advance the Africa Health Security and Sovereignty (AHSS) Agenda.
Scope of Supply
The requirement is divided into two Lots:
● Lot 1 – Yellow Fever Vaccine
● Lot 2 – Hexavalent Vaccine
Bidders may bid for one or both Lots. More than one Framework Agreement may be awarded per Lot. Each Framework Agreement will run for thirty-six (36) months. Purchases will be made through individual Call-off Contracts issued during that period against confirmed requirements submitted by participating Member States.
Eligibility Requirements
Bidders shall demonstrate, at a minimum:
● a valid manufacturing licence and Good Manufacturing Practice (GMP) certification for the manufacturing site offered;
● a valid marketing authorisation or product registration for the vaccine and presentation offered;
● WHO Prequalification or other acceptable regulatory status, where required for the vaccine concerned;
● validated cold-chain packaging, shipping and temperature-monitoring capability;
● and manufacturing capacity, production lead times and quality systems sufficient to meet Call-off requirements.
Full eligibility and qualification requirements are set out in Section I and Section III of the Bidding Document.